458 related articles for article (PubMed ID: 34390203)
1. Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinoma.
Xia Y; Brown ZJ; Huang H; Tsung A
Cancer Med; 2021 Sep; 10(18):6374-6383. PubMed ID: 34390203
[TBL] [Abstract][Full Text] [Related]
2. The role of tumor-associated macrophages in primary hepatocellular carcinoma and its related targeting therapy.
Deng L; He K; Pan Y; Wang H; Luo Y; Xia Q
Int J Med Sci; 2021; 18(10):2109-2116. PubMed ID: 33859517
[TBL] [Abstract][Full Text] [Related]
3. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
Zhang Q; Lou Y; Bai XL; Liang TB
World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
[TBL] [Abstract][Full Text] [Related]
4. Recent progress in the emerging role of exosome in hepatocellular carcinoma.
Abudoureyimu M; Zhou H; Zhi Y; Wang T; Feng B; Wang R; Chu X
Cell Prolif; 2019 Mar; 52(2):e12541. PubMed ID: 30397975
[TBL] [Abstract][Full Text] [Related]
5. Macrophages as Targets in Hepatocellular Carcinoma Therapy.
Liu YT; Mao ZW; Ding Y; Wang WL
Mol Cancer Ther; 2024 Jun; 23(6):780-790. PubMed ID: 38310642
[TBL] [Abstract][Full Text] [Related]
6. Annexin A2 promotion of hepatocellular carcinoma tumorigenesis
Qiu LW; Liu YF; Cao XQ; Wang Y; Cui XH; Ye X; Huang SW; Xie HJ; Zhang HJ
World J Gastroenterol; 2020 May; 26(18):2126-2137. PubMed ID: 32476780
[TBL] [Abstract][Full Text] [Related]
7. Neutrophils: Driving inflammation during the development of hepatocellular carcinoma.
Chen H; Zhou XH; Li JR; Zheng TH; Yao FB; Gao B; Xue TC
Cancer Lett; 2021 Dec; 522():22-31. PubMed ID: 34517084
[TBL] [Abstract][Full Text] [Related]
8. Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer.
O'Rourke JM; Sagar VM; Shah T; Shetty S
World J Gastroenterol; 2018 Oct; 24(39):4436-4447. PubMed ID: 30357021
[TBL] [Abstract][Full Text] [Related]
9. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities.
Lu C; Rong D; Zhang B; Zheng W; Wang X; Chen Z; Tang W
Mol Cancer; 2019 Aug; 18(1):130. PubMed ID: 31464625
[TBL] [Abstract][Full Text] [Related]
10. Group-2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2-Neutrophil-Induced Immunosuppression.
Xu X; Ye L; Zhang Q; Shen H; Li S; Zhang X; Ye M; Liang T
Hepatology; 2021 Nov; 74(5):2526-2543. PubMed ID: 33829508
[TBL] [Abstract][Full Text] [Related]
11. Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression.
Wu Q; Zhou L; Lv D; Zhu X; Tang H
J Hematol Oncol; 2019 May; 12(1):53. PubMed ID: 31142326
[TBL] [Abstract][Full Text] [Related]
12. Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma.
Rohr-Udilova N; Klinglmüller F; Schulte-Hermann R; Stift J; Herac M; Salzmann M; Finotello F; Timelthaler G; Oberhuber G; Pinter M; Reiberger T; Jensen-Jarolim E; Eferl R; Trauner M
Sci Rep; 2018 Apr; 8(1):6220. PubMed ID: 29670256
[TBL] [Abstract][Full Text] [Related]
13. The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review.
Schoenberg MB; Li X; Li X; Han Y; Börner N; Koch D; Guba MO; Werner J; Bazhin AV
Int Immunopharmacol; 2021 Dec; 101(Pt A):108220. PubMed ID: 34673334
[TBL] [Abstract][Full Text] [Related]
14. Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications.
Sung PS; Jang JW
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30463262
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Liver Microenvironment during Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish.
Michael C; Martínez-Navarro FJ; de Oliveira S
J Vis Exp; 2021 Apr; (170):. PubMed ID: 33871465
[TBL] [Abstract][Full Text] [Related]
16. Intrahepatic metastases may be specific to hepatocellular carcinoma due to the coagulation and fibrinolytic systems (Review).
Li X; Gu B; Wang B; Feng Z; Ma Y; Li H; Lucas A; Chen H
Oncol Rep; 2020 Dec; 44(6):2345-2352. PubMed ID: 33125140
[TBL] [Abstract][Full Text] [Related]
17. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
18. Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages.
Zhou J; Wang W; Li Q
J Exp Clin Cancer Res; 2021 Feb; 40(1):73. PubMed ID: 33596985
[TBL] [Abstract][Full Text] [Related]
19. Transient Kupffer cell depletion and subsequent replacement by infiltrating monocyte-derived cells does not alter the induction or progression of hepatocellular carcinoma.
Vanderborght B; De Muynck K; Gijbels E; Lefere S; Scott CL; Guilliams M; Beschin A; Vinken M; Verhelst X; Geerts A; Van Vlierberghe H; Devisscher L
Int J Cancer; 2023 Jun; 152(12):2615-2628. PubMed ID: 36912275
[TBL] [Abstract][Full Text] [Related]
20. CNOT7 depletion reverses natural killer cell resistance by modulating the tumor immune microenvironment of hepatocellular carcinoma.
Ren C; Ren X; Cao D; Zhao H; Zhai Z; Li H; Li Y; Fu X; He J; Zhao H
FEBS Open Bio; 2020 May; 10(5):847-860. PubMed ID: 32160402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
